The TBCRC-056 trial showed a 50% pCR rate in TNBC patients with BRCA or PALB2 mutations treated with niraparib and dostarlimab. sTILs increased significantly in both treatment arms, with higher ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

Discover how a weakening labor market impacted the SLNZ ETF's 1.28% Q3 2025 gain. Click here to learn about our strategy for ...

Among the pesticides and herbicides used on the family’s Michigan farm, she said, was a substance called paraquat, a ...

BSEH Haryana Board 9th Science Model Paper 2026 is an essential practice resource for students preparing for their annual ...